Precision Psychiatry Platform Guides Depression Treatment Choices with Talia Cohen Solal NeuroKaire

Talia Cohen Solal, CEO and Co-Founder of NeuroKaire, is focused on improving patient outcomes of those with depression by predicting the most effective antidepressant for each individual. The NeuroKaire platform personalizes psychiatric treatment by creating neurons from a patient's blood sample to model their brain and test drug responses, pointing the way to an effective treatment, avoiding prolonged trial-and-error. This is a significant advancement over existing pharmacogenomic tests, which primarily provide information on drug metabolism rather than drug efficacy. This technology is also being applied to other conditions like ADHD, schizophrenia, bipolar disorder, and epilepsy.   Talia explains, "At NeuroKaire, we are dedicated to improving patient outcomes in psychiatry and neurology. To do that, we've developed a platform to predict which antidepressant is best for each patient and are expanding out to other disease indications to achieve that mission."   "Basically, around 2006, Yamanaka and his colleagues discovered that you could take any cell in the body and turn it back into a stem cell. And that changed everything for the field. So what we can do now is we can take a blood sample, turn it back into a stem cell, and then turn it into whatever cell type we'd like. And our mission is to help people with brain disorders and psychiatric disorders. And so we turn those stem cells into neurons. And now we have a model of the patient's brain. Now we have neurons from the patient's brain and a little ecosystem mimicking a patient's brain. And there we can actually see what's going wrong in the connectivity, what's changed in those patients, and what drugs are going to have the best outcome to reverse those changes." #NeuroKaire #PrecisionPsychiatry #MentalHealth #Antidepressants #BrightKaire #PersonalizedMedicine #PGx #Neuroscience #HealthcareInnovation neurokaire.com Download the transcript here